The Thai Journal of Veterinary Medicine
https://he01.tci-thaijo.org/index.php/tjvm
<p><em>The Thai Journal of Veterinary Medicine</em> publishes articles reporting interdisciplinary investigations concerning veterinary and animal sciences, at all levels of resolution, from basic to clinical, molecular to behavioral, and opinions that are of general interest to the broad community of veterinarians and biological scientists. Clinical or pathological investigations, protocols and reviews will also be considered for publication if they provide significant insight into the structure or function, the pathophysiology of a disease, or its treatment. </p>en-US[email protected] (Professor Dr.Padet Tummaruk)[email protected] (Mr.Kritsana Phanchinda)Wed, 07 Feb 2024 16:19:54 +0700OJS 3.3.0.8http://blogs.law.harvard.edu/tech/rss60Long-term tapering regimen use of oclacitinib for the control of pruritus in an atopic dog
https://he01.tci-thaijo.org/index.php/tjvm/article/view/268883
<p>Canine atopic dermatitis (CAD) is a genetically predisposed inflammatory skin disease with a global distribution, yet it is incurable. A key clinical sign of CAD is pruritus. Oclacitinib has proven effective in managing pruritus in atopic dogs. This case report details the long-term administration of oclacitinib every other day for controlling pruritus in an atopic dog. An 8-year-old atopic Bangkaew dog presented with pruritus, alopecia, and recurrent Malassezia pachydermatis infection. To control the pruritus, the dog received oclacitinib at a dose of 0.4 mg/kg orally every 24 hours for 30 weeks. The pruritus visual analog scale (PVAS) decreased from 8/10 to 4/10 by week 2, and the skin lesions improved by week 18. After 30 weeks, with improved skin lesions and a stable PVAS at 2/10, the dosing frequency of oclacitinib was reduced to every other day, supplemented with hydroxyzine on the days without oclacitinib. This adjustment maintained the PVAS and skin condition at levels comparable to before the tapering of oclacitinib. No clinical abnormalities were observed during the 12 months of treatment under the tapered regimen of oclacitinib at 0.4 mg/kg orally every other day. This is the first report of successful pruritus management in an atopic dog using a tapering regimen of oclacitinib.</p>Piyarat Chansiripornchai, Pornphan Sukanan
Copyright (c) 2024
http://creativecommons.org/licenses/by-nc-nd/4.0
https://he01.tci-thaijo.org/index.php/tjvm/article/view/268883Wed, 07 Feb 2024 00:00:00 +0700